289 related articles for article (PubMed ID: 18504642)
1. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
[TBL] [Abstract][Full Text] [Related]
2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
5. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
[TBL] [Abstract][Full Text] [Related]
7. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer.
Hatoum HA; Jamali FR; El-Saghir NS; Musallam KM; Seoud M; Dimassi H; Abbas J; Khalife M; Boulos FI; Tawil AN; Geara FB; Salem Z; Shamseddine AA; Al-Feghali K; Shamseddine AI
Ann Surg Oncol; 2009 Dec; 16(12):3388-95. PubMed ID: 19655200
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
[TBL] [Abstract][Full Text] [Related]
14. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
Tiezzi DG; Andrade JM; Ribeiro-Silva A; Zola FE; Marana HR; Tiezzi MG
BMC Cancer; 2007 Feb; 7():36. PubMed ID: 17324279
[TBL] [Abstract][Full Text] [Related]
15. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis.
Nishimura R; Osako T; Okumura Y; Hayashi M; Arima N
Breast Cancer; 2010 Oct; 17(4):269-75. PubMed ID: 19730975
[TBL] [Abstract][Full Text] [Related]
17. Locoregional recurrence of breast cancer: a retrospective comparison of treatment methods.
Skowronek J; Piotrowski T
Neoplasma; 2002; 49(6):426-31. PubMed ID: 12584593
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival outcomes following internal mammary node irradiation in stage II-III breast cancer: results of a large retrospective study with 12-year follow-up.
Chang JS; Park W; Kim YB; Lee IJ; Keum KC; Lee CG; Choi DH; Suh CO; Huh SJ
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):867-72. PubMed ID: 23747215
[TBL] [Abstract][Full Text] [Related]
19. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
[TBL] [Abstract][Full Text] [Related]
20. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S; Catena F; Santini D; Ansaloni L; Fogacci T; Mignani S; Leone A; Gazzotti F; Gagliardi S; De Cataldis A; Taffurelli M
Breast Cancer Res Treat; 2008 Jun; 109(3):405-16. PubMed ID: 17687650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]